SLU-PP-332

Structure: Small-molecule pan-agonist of all three ERR isoforms (ERRα, ERRβ, ERRγ). Despite the name, NOT a peptide — commonly grouped with peptides commercially because it ships from the same research-chem vendors. Developed at Saint Louis University (hence "SLU").

Dosage:

• No established human dose — all data is from rodent studies
• Vendor-suggested SubQ: 5-10mg, 3-5x/week (extrapolated from mouse studies, unvalidated)
• Mouse studies: 50mg/kg/day intraperitoneal (does NOT translate directly to human dosing)
• Cycle: Unknown — most users run 4-8 weeks based on anecdote

Administration:

• SubQ injection (vendor convention) with 27-30g insulin syringe
• Reconstitute with bacteriostatic water; some sources recommend DMSO + BAC water due to solubility
• Some users dose orally — bioavailability is poorly characterised

Key Notes:

• "Exercise mimetic" — activates ERR-driven transcription of mitochondrial biogenesis genes (PGC-1α pathway) without requiring exercise
• In mice: 70% longer time-to-exhaustion on treadmill, increased type I muscle fibres, improved glucose tolerance, reduced fat mass on high-fat diet
• Distinct from MOTS-C (AMPK activator) — may stack synergistically
• Bodybuilding/anecdotal claims: improved cardio capacity, fat loss, "second wind" on cardio sessions
• ZERO human clinical trials. ZERO long-term safety data. Off-target effects on cardiac ERR signalling are theoretically concerning (cardiac hypertrophy was seen at high doses in mice)
• Vendor purity highly variable — third-party HPLC testing strongly recommended
• Not detected on standard sports drug panels (novel research chemical, no validated assay)
• Bodybuilding relevance: experimental endurance/recomp aid; risk profile unknown
• Monitor (precautionary): liver enzymes (ALT, AST), lipid panel, fasting glucose, blood pressure, resting heart rate, ECG if used for >4 weeks